A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-12-29
Adverse events
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-06-26 (study day 166); relationship: N
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-02 (study day 356); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 365); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-24 (study day 409); relationship: not assessed; serious criteria: life-threatening
Grade 1 Neutropenia — outcome: UNKNOWN; onset 2024-03-07 (study day 421); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-28 (study day 595); relationship: Y
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-20 (study day 679); relationship: N
Data queries
No data queries.